ALPINE IMMUNE SCIENCES INC (ALPN)
US02083G1004 - Common Stock
We assign a fundamental rating of 4 out of 10 to ALPN. ALPN was compared to 588 industry peers in the Biotechnology industry. While ALPN has a great health rating, there are worries on its profitability. ALPN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ALPN has reported negative net income.
ALPN had a negative operating cash flow in the past year.
In the past 5 years ALPN always reported negative net income.
In the past 5 years ALPN reported 4 times negative operating cash flow.
1.2 Ratios
ALPN's Return On Assets of -8.47% is amongst the best of the industry. ALPN outperforms 90.27% of its industry peers.
Looking at the Return On Equity, with a value of -9.82%, ALPN belongs to the top of the industry, outperforming 91.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.47% | ||
| ROE | -9.82% | ||
| ROIC | N/A |
ROA(3y)-16.1%
ROA(5y)-29.01%
ROE(3y)-27.88%
ROE(5y)-54.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ALPN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALPN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALPN has been increased compared to 5 years ago.
There is no outstanding debt for ALPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ALPN has an Altman-Z score of 48.68. This indicates that ALPN is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 48.68, ALPN belongs to the best of the industry, outperforming 97.44% of the companies in the same industry.
There is no outstanding debt for ALPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 48.68 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
ALPN has a Current Ratio of 7.86. This indicates that ALPN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.86, ALPN is in the better half of the industry, outperforming 72.18% of the companies in the same industry.
ALPN has a Quick Ratio of 7.86. This indicates that ALPN is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.86, ALPN is doing good in the industry, outperforming 72.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.86 | ||
| Quick Ratio | 7.86 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.12% over the past year.
Looking at the last year, ALPN shows a very strong growth in Revenue. The Revenue has grown by 95.79%.
ALPN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 141.96% yearly.
EPS 1Y (TTM)60.12%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q129.27%
Revenue 1Y (TTM)95.79%
Revenue growth 3Y84.73%
Revenue growth 5Y141.96%
Revenue growth Q2Q1009.82%
3.2 Future
The Earnings Per Share is expected to decrease by -3.94% on average over the next years.
ALPN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.71% yearly.
EPS Next Y-157.63%
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
EPS Next 5Y-3.94%
Revenue Next Year-56.25%
Revenue Next 2Y-32.39%
Revenue Next 3Y-34.72%
Revenue Next 5Y36.71%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALPN. In the last year negative earnings were reported.
Also next year ALPN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ALPN's earnings are expected to decrease with -54.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
5. Dividend
5.1 Amount
ALPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALPINE IMMUNE SCIENCES INC
NASDAQ:ALPN (5/2/2024, 9:27:08 AM)
64.605
+0.01 (+0.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.23B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.47% | ||
| ROE | -9.82% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.86 | ||
| Quick Ratio | 7.86 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)60.12%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-157.63%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)95.79%
Revenue growth 3Y84.73%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y